In the last trading session, 2.6 million shares of the Oncolytics Biotech, Inc. (NASDAQ:ONCY) were traded, and its beta was 1.64. Most recently the company’s share price was $1.27, and it changed around -$0.13 or -9.29% from the last close, which brings the market valuation of the company to $97.78M. ONCY currently trades at a discount to its 52-week high of $2.07, offering almost -62.99% off that amount. The share price’s 52-week low was $0.84, which indicates that the current value has risen by an impressive 33.86% since then. We note from Oncolytics Biotech, Inc.’s average daily trading volume that its 10-day average is 1.05 million shares, with the 3-month average coming to 275.58K.
Oncolytics Biotech, Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 1.12. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended ONCY as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Oncolytics Biotech, Inc. is expected to report earnings per share of -0.07 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Oncolytics Biotech, Inc. (NASDAQ:ONCY) trade information
Instantly ONCY has showed a red trend with a performance of -9.29% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.5300 on recent trading dayincreased the stock’s daily price by 16.99%. The company’s shares are currently down -5.93% year-to-date, but still up 47.50% over the last five days. On the other hand, Oncolytics Biotech, Inc. (NASDAQ:ONCY) is 36.56% up in the 30-day period. We can see from the shorts that 0.69 million shares have been sold at a short interest cover period of 3.94 day(s).
Oncolytics Biotech, Inc. (ONCY) estimates and forecasts
Oncolytics Biotech, Inc. share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 9.48 percent over the past six months and at a 3.33% annual growth rate that is well below the industry average of 17.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 30.00% in revenue this quarter, and will report a decrease of -75.00% in the next quarter.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 18.01%.
ONCY Dividends
Oncolytics Biotech, Inc.’s next quarterly earnings report is expected to be released in November.
Oncolytics Biotech, Inc. (NASDAQ:ONCY)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.82% of Oncolytics Biotech, Inc. shares, and 1.75% of them are in the hands of institutional investors. The stock currently has a share float of 1.82%. Oncolytics Biotech, Inc. stock is held by 44.0 institutions, with INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC being the largest institutional investor. By 2024-06-30, it held 0.2637% of the shares, which is about 0.2 million shares worth $0.2 million.
SEEDS INVESTOR LLC, with 0.2524% or 0.19 million shares worth $0.19 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
